• If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease
    • Potential for ENTYVIO to address pediatric treatment gaps, reflecting Takeda's commitment to advancing options where unmet treatment needs remain